Expansion Opportunities Skyhawk is actively expanding US trial sites with a planned five active sites by year-end, signaling a growing need for local clinical operations support, site management, patient recruitment partners, and CRO services to accelerate trial timelines.

Huntington’s Focus With SKY-0515 advancing toward Huntington’s disease commercialization, there is a clear target for neurology-focused contract research, regulatory strategy advice, biomarker development partnerships, and payer/reimbursement strategists to support market access.

Strategic Collaborations Ongoing and announced collaborations with Merck KGaA and international partners suggest opportunities to offer RNA-targeting drug discovery platforms, translational analytics, and co-development services to strengthen neuro-oncology and neurological disease pipelines.

RNA Targeting Demand Specialization in small molecule RNA-targeting therapeutics positions Skyhawk to collaborate with bioinformatics, cheminformatics, and high-throughput screening vendors, as well as specialized manufacturing and scale-up partners for RNA-modulating candidates.

Clinical and Commercial Readiness Revenue and funding levels indicate a company gearing up for scale; sales opportunities exist in market access, medical affairs, commercial planning, and regional advocacy engagement to prepare for launch readiness and physician education in neurology and oncology spaces.